Data are represented as mean ± SD and median with interquartile range.
References
1. Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford, England). 2012;51(4):721-9.
2. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and rheumatism. 2010;62(9):2569-81.
3. Zhao J, Su Y, Li R, Ye H, Zou Q, Fang Y, et al. Classification criteria of early rheumatoid arthritis and validation of its performance in a multi-centre cohort. Clin Exp Rheumatol. 2014;32(5):667-73.
4. Burgers LE, van Steenbergen HW, Ten Brinck RM, Huizinga TW, van der Helm-van Mil AH. Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Annals of the rheumatic diseases. 2017;76(10):1751-4.
5. Ding B, Padyukov L, Lundstrom E, Seielstad M, Plenge RM, Oksenberg JR, et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis and rheumatism. 2009;60(1):30-8.
6. Belakova G, Manka V, Zanova E, Racay P. Benefits of anticitrullinated peptides examination in rheumatoid arthritis. Nigerian journal of clinical practice. 2018;21(10):1380-3.
7. Im CH, Kang EH, Ryu HJ, Lee JH, Lee EY, Lee YJ, et al. Anti-cyclic citrullinated peptide antibody is associated with radiographic erosion in rheumatoid arthritis independently of shared epitope status. Rheumatology international. 2009;29(3):251-6.
8. Cheng TT, Yu SF, Su FM, Chen YC, Su BY, Chiu WC, et al. Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX(R): a registry study of RA with osteoporosis/fracture. Arthritis research & therapy. 2018;20(1):16.
9. Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Annals of the rheumatic diseases. 2015;74(12):2151-6.
10. Schett G. The role of ACPAs in at-risk individuals: Early targeting of the bone and joints. Best practice & research Clinical rheumatology. 2017;31(1):53-8.
11. England BR, Thiele GM, Mikuls TR. Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis. Current opinion in rheumatology. 2017;29(1):57-64.
12. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Annals of the rheumatic diseases. 2011;70(2):259-65.
13. Viatte S, Plant D, Bowes J, Lunt M, Eyre S, Barton A, et al. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Annals of the rheumatic diseases. 2012;71(12):1984-90.
14. Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford, England). 2016;55(2):199-209.
15. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome research. 2008;18(9):1509-17.
16. Heruth DP, Gibson M, Grigoryev DN, Zhang LQ, Ye SQ. RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis. Cell & bioscience. 2012;2(1):43.
17. Adamopoulos IE, Chao CC, Geissler R, Laface D, Blumenschein W, Iwakura Y, et al. Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis research & therapy. 2010;12(1):R29.
18. Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, et al. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Annals of the rheumatic diseases. 2012;71(8):1374-81.
19. Wright HL, Cox T, Moots RJ, Edwards SW. Neutrophil biomarkers predict response to therapy with tumor necrosis factor inhibitors in rheumatoid arthritis. Journal of leukocyte biology. 2017;101(3):785-95.
20. Yu F, Duan C, Zhang X, Yao D, Si G, Gao Y, et al. RNA-seq analysis reveals different gene ontologies and pathways in rheumatoid arthritis and Kashin-Beck disease. International journal of rheumatic diseases. 2018;21(9):1686-94.
21. Sumitomo S, Nagafuchi Y, Tsuchida Y, Tsuchiya H, Ota M, Ishigaki K, et al. Transcriptome analysis of peripheral blood from patients with rheumatoid arthritis: a systematic review. Inflammation and regeneration. 2018;38:21.
22. Wolpe SD, Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J. 1989;3(14):2565-73.
23. De Filippo K, Dudeck A, Hasenberg M, Nye E, van Rooijen N, Hartmann K, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013;121(24):4930-7.
24. Gang X, Sun Y, Li F, Yu T, Jiang Z, Zhu X, et al. Identification of key genes associated with rheumatoid arthritis with bioinformatics approach. Medicine. 2017;96(31):e7673.
25. Jacobs JP, Ortiz-Lopez A, Campbell JJ, Gerard CJ, Mathis D, Benoist C. Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis and rheumatism. 2010;62(7):1921-32.
26. Ha J, Choi HS, Lee Y, Kwon HJ, Song YW, Kim HH. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis. Journal of immunology (Baltimore, Md : 1950). 2010;184(9):4717-24.
27. Boro M, Balaji KN. CXCL1 and CXCL2 Regulate NLRP3 Inflammasome Activation via G-Protein-Coupled Receptor CXCR2. Journal of immunology (Baltimore, Md : 1950). 2017;199(5):1660-71.
28. Henn D, Abu-Halima M, Wermke D, Falkner F, Thomas B, Kopple C, et al. MicroRNA-regulated pathways of flow-stimulated angiogenesis and vascular remodeling in vivo. Journal of translational medicine. 2019;17(1):22.
29. Subat S, Mogushi K, Yasen M, Kohda T, Ishikawa Y, Tanaka H. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma. Journal of cancer research and clinical oncology. 2019;145(3):675-84.
30. Lu J, Xu W, Qian J, Wang S, Zhang B, Zhang L, et al. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. BMC medical genomics. 2019;12(Suppl 2):38.
31. Ha J, Lee Y, Kim HH. CXCL2 mediates lipopolysaccharide-induced osteoclastogenesis in RANKL-primed precursors. Cytokine. 2011;55(1):48-55.
32. Cheng Y, Ma XL, Wei YQ, Wei XW. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases. Biochim Biophys Acta Rev Cancer. 2019;1871(2):289-312.
33. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Molecules and cells. 2017;40(10):706-13.
34. Song F, Zhou L, Zhao J, Liu Q, Yang M, Tan R, et al. Eriodictyol Inhibits RANKL-Induced Osteoclast Formation and Function Via Inhibition of NFATc1 Activity. Journal of cellular physiology. 2016;231(9):1983-93.
35. Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri C, et al. Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. British journal of pharmacology. 2008;153(5):992-1002.
36. Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, Lundell D, et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochemical and biophysical research communications. 2010;391(1):1080-6.
37. Kim SJ, Chen Z, Essani AB, Elshabrawy HA, Volin MV, Fantuzzi G, et al. Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status. Annals of the rheumatic diseases. 2017;76(4):731-9.